Characteristics | N (%) |
---|---|
Demographic characteristics | |
Male | 17 (77) |
Median age at onset of arthritis, yrs (IQR) | 10.4 (0.4–12.0) |
Median disease duration before start of anti-TNF, yrs (IQR) | 3.1 (1.1–5.9) |
Disease characteristics | |
Presence of HLA-B27 antigen | 15 (68) |
≤ 4 active joints at start of anti-TNF | 7 (32) |
> 4 active joints at start of anti-TNF | 15 (68) |
Enthesitis | 17 (77) |
In Achilles tendon | 13 (76) |
History of sacroiliac joint tenderness and/or inflammatory lumbosacral pain | 12 (55) |
Onset of arthritis in male > 6 yrs old | 16 (73) |
Anterior uveitis | 0 (0) |
Family history of HLA-B27-related disease | 12 (55) |
Medication history before start of anti-TNF therapy | |
NSAID | 21 (96) |
Systemic glucocorticoids | 8 (36) |
Intraarticular glucocorticoids | 4 (18) |
Methotrexate | 21 (96) |
Sulfasalazine | 17 (77) |
Leflunomide | 2 (9) |
Azathioprine | 1 (5) |
Concomitant medications at start of anti-TNF therapy | |
NSAID | 19 (86) |
Systemic glucocorticoids | 3 (14) |
Methotrexate | 17 (77) |
Sulfasalazine | 2 (9) |
Leflunomide | 0 (0) |
Azathioprine | 0 (0) |
IQR: interquartile range; TNF: tumor necrosis factor; NSAID: nonsteroidal antiinflammatory drugs.